(Q49546562)

English

BRD4 profiling identifies critical Chronic Lymphocytic Leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor.

scientific article published on 31 January 2018

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

BRD4 profiling identifies critical Chronic Lymphocytic Leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor. (English)

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

0 references

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

Nicole R Grieselhuber

object named as

Nicole R Grieselhuber

8

0 references

Bonnie K Harrington

object named as

Bonnie Harrington

6

0 references

45

object named as

Gideon Bollag

1 reference

Europe PubMed Central

21 February 2018

29

object named as

Rafe Shellooe

1 reference

Europe PubMed Central

21 February 2018

41

object named as

Gaston Habets

1 reference

Europe PubMed Central

21 February 2018

46

object named as

John C Byrd

1 reference

Europe PubMed Central

21 February 2018

44

object named as

Ewy A Mathé

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

author name string

Hatice Gulcin Ozer

1

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Dalia El-Gamal

2

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Ben Powell

3

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Zachary A Hing

4

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

James S Blachly

5

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Shaneice Mitchell

7

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Katie Williams

9

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Tzung-Huei Lai

10

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Lapo Alinari

11

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Robert A Baiocchi

12

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Lindsey Brinton

13

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Elizabeth Baskin

14

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Matthew Cannon

15

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Larry Beaver

16

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Virginia M Goettl

17

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

David M Lucas

18

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Jennifer A Woyach

19

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Deepa Sampath

20

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Amy M Lehman

21

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Lianbo Yu

22

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Jiazhong Zhang

23

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Yan Ma

24

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Ying Zhang

25

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Wayne Spevak

26

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Songyuan Shi

27

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Paul Severson

28

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Heidi Carias

30

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Garson Tsang

31

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Ken Dong

32

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Todd Ewing

33

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Adhirai Marimuthu

34

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Christina Tantoy

35

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Jason Walters

36

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Laura Sanftner

37

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Hamid Rezaei

38

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Marika Nespi

39

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Bernice Matusow

40

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Prabha Ibrahim

42

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Chao Zhang

43

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Rosa Lapalombella

47

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

publication date

31 January 2018

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Cancer Discovery

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

IL-4 enhances expression and function of surface IgM in CLL cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Active medulloblastoma enhancers reveal subgroup-specific cellular origins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Mutations driving CLL and their evolution in progression and relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Chemical intervention of the NM23-H2 transcriptional programme on c-MYC via a novel small molecule

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Targeted therapies in CLL: mechanisms of resistance and strategies for management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

The mechanisms behind the therapeutic activity of BET bromodomain inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

BET bromodomains mediate transcriptional pause release in heart failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Selective inhibition of tumor oncogenes by disruption of super-enhancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Transcriptional amplification in tumor cells with elevated c-Myc.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Targeting epigenetic readers in cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Targeting MYC dependence in cancer by inhibiting BET bromodomains

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Bromodomains as therapeutic targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Analysis of the coding genome of diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Selective inhibition of BET bromodomains

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

From pathogenesis to treatment of chronic lymphocytic leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

The TCL1 family of oncoproteins: co-activators of transformation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Overexpression of cyclin D2 in chronic B-cell malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Lymphocytic lymphoma/B-chronic lymphocytic leukaemia--an immunohistopathological study of peripheral B lymphocyte neoplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

26 August 2018

Non-coding recurrent mutations in chronic lymphocytic leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5882533

2 November 2018

Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1)

1 reference

https://pubmed.ncbi.nlm.nih.gov/29386193

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/29386193

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development

1 reference

https://pubmed.ncbi.nlm.nih.gov/29386193

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TCL1 is activated by chromosomal rearrangement or by hypomethylation

1 reference

https://pubmed.ncbi.nlm.nih.gov/29386193

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gene expression profiling of the functionally distinct human bone marrow stromal cell lines HS-5 and HS-27a

1 reference

https://pubmed.ncbi.nlm.nih.gov/29386193

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/29386193

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state

1 reference

https://pubmed.ncbi.nlm.nih.gov/29386193

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single-cell-derived mesenchymal stem cells overexpressing Csx/Nkx2.5 and GATA4 undergo the stochastic cardiomyogenic fate and behave like transient amplifying cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/29386193

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The IKZF3 (Aiolos) transcription factor is highly upregulated and inversely correlated with clinical progression in chronic lymphocytic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/29386193

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genome-wide surveillance of mismatched alleles for graft-versus-host disease in stem cell transplantation.

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1158/2159-8290.CD-17-0902

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

1 reference

5 May 2024

https://opencitations.net/index/api/v1/references/10.1158/2159-8290.CD-17-0902

Identifiers

10.1158/2159-8290.CD-17-0902

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

0 references

1 reference

Europe PubMed Central

21 February 2018

http://europepmc.org/abstract/MED/29386193

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q49546562&oldid=2146768813"